Streetbeat News

Revenues

NBIX

Neurocrine Biosciences has projected its Ingrezza (Valbenazine) net product sales for the full year 2024 to be between $2.1 billion and $2.2 billion.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 12:07 pm

NBIX

Neurocrine Biosciences announced Q4 and FY23 net product sales for Ingrezza (valbenazine) of $500M and $1.84B, showing year-over-year growth of 25% and 29% respectively.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 12:06 pm

MAC

Macerich (NYSE:MAC) reported Q4 2023 earnings of $0.56 per share, meeting analyst consensus estimates. Quarterly sales reached $238.69 million, surpassing the $224.53 million estimate by 6.31% and marking a 4.58% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 12:05 pm

ACM

Aecom announced that several of its projects for major U.S. transportation clients have secured approximately $16.4 billion in funding from the Federal-State Partnership for Intercity Passenger Rail Grant Program. This funding will support Aecom's ongoing and future projects in the U.S. transportation sector.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 12:00 pm

FMC

Analysts have provided diverse ratings for FMC (NYSE:FMC), with a recent shift towards more neutral stances. The average 12-month price target has been adjusted to $64.2, down from $69.29, reflecting a 7.35% decline. FMC's financial performance shows strong revenue growth, net margin, ROE, and ROA, but faces challenges in debt management. The company is a major player in the global crop protection industry, focusing on patented products and R&D for new biologicals.

Portfolio Pulse from Benzinga Insights

February 07, 2024 | 12:00 pm

ADNT

Adient has reaffirmed its fiscal year 2024 sales forecast, expecting revenues to be between $15.4 billion and $15.5 billion, slightly below the analyst estimate of $15.59 billion. The company also projects its adjusted EBITDA to reach $985 million in FY24.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 11:59 am

CG

Carlyle Group (NASDAQ:CG) reported a Q4 2023 GAAP EPS loss of $(1.92) per share, with quarterly sales of $926.20 million, surpassing analyst expectations by 8.92% but marking a 12.54% decrease from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 11:55 am

IMOS

ChipMOS reported a 28.4% year-over-year increase in consolidated revenue for January 2024, despite a 9.2% decrease from December 2023. The revenue for January 2024 was NT$1,708.5 million or US$54.6 million.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 11:37 am

GGR

Gogoro anticipates generating revenue between $385M-$420M in 2024, with around 90% coming from the Taiwan market and 10% from international markets.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 11:22 am

BG

Bunge (NYSE:BG) reported Q4 sales of $14.94 billion, missing the consensus estimate of $15.06 billion by 0.82% and marking a 10.35% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 11:14 am